Leading Cancer Researcher Fails To Disclose Corporate Payments

J&J and Bayer fail ... Corporation (INCY) Jakafi drug. Gilead didn't get too much upfront for the drug, it obtained approximately $3 million upfront for it. If the drug does achieve some good results, ...

Source : https://seekingalpha.com/article/4202288-biotech-analysis-central-pharma-news-j-and-j-bayer-failure-gilead-sciences-unloads-cancer

44